Autres langues Geron Corporation

Actions

GERN

US3741631036

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 04/09/2026			Varia. 5j.	Varia. 1 janv.
1,570 ^USD	+3,97%		+3,97%	+18,94%

05/08	Geron Corporation publie ses prévisions de résultats pour 2026	CI
05/08	Geron Corporation publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

02/09	Geron to Present at Upcoming Investor Conferences
18/08	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/08	Geron Corporation Provides Earnings Guidance for 2026
05/08	Geron Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Earnings Flash (GERN) Geron Corporation Reports Q2 Revenue $57.5M, vs. FactSet Est of $55.3M
05/08	Earnings Flash (GERN) Geron Corporation Reports Q2 Revenue $57.5M, vs. FactSet Est of $55.3M
05/08	Geron: Q2 Earnings Snapshot
05/08	Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
23/07	Geron Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
22/07	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22/07	Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
15/07	Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 14, 2026
14/07	Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
13/07	Geron Corporation Announces Appointment of Chinmaya Rath as Chief Business Officer
13/07	Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
19/06	Geron Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
18/06	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/06	Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
20/05	Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
18/05	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/05	First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
12/05	Geron Corporation Presents First Real-World Evidence Study of Rytelo in Lower-Risk Myelodysplastic Syndromes
06/05	Geron Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026
06/05	Geron Shares Fall After Reporting Q1 Results
06/05	Geron : Corporate Presentation